N

NeuBase Therapeutics Inc
F:O7PA

Watchlist Manager
NeuBase Therapeutics Inc
F:O7PA
Watchlist
Price: 0.159 EUR -3.64%
Market Cap: 107.5m EUR

Intrinsic Value

O7PA doesn't have a meaningful market cap.

There is not enough data to reliably calculate the intrinsic value of O7PA.

The Intrinsic Value is calculated as the average of DCF and Relative values:

O7PA Intrinsic Value
Not Available
N
Base Case Scenario
Compare O7PA to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about O7PA?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
NeuBase Therapeutics Inc

Current Assets 13.4m
Cash & Short-Term Investments 12.6m
Other Current Assets 780k
Non-Current Assets 5.3m
PP&E 5.1m
Other Non-Current Assets 130k
Current Liabilities 4.7m
Accounts Payable 260k
Accrued Liabilities 960k
Other Current Liabilities 3.4m
Non-Current Liabilities 4.8m
Other Non-Current Liabilities 4.8m
Efficiency

Free Cash Flow Analysis
NeuBase Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
NeuBase Therapeutics Inc

Revenue
0 USD
Operating Expenses
-13.4m USD
Operating Income
-13.4m USD
Other Expenses
-350k USD
Net Income
-13.7m USD
Fundamental Scores

O7PA Profitability Score
Profitability Due Diligence

NeuBase Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Low 3Y Average Net Margin
Low 3Y Average Operating Margin
Declining ROE
21/100
Profitability
Score

NeuBase Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

O7PA Solvency Score
Solvency Due Diligence

NeuBase Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
53/100
Solvency
Score

NeuBase Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

O7PA Price Targets Summary
NeuBase Therapeutics Inc

There are no price targets for O7PA.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for O7PA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y